Novotech kicks off Phase Ib trials in Australia and NZ for OncoMed

By Staff Writers
Wednesday, 03 November, 2010

California-based biopharma company, OncoMed Pharmaceuticals, has announced it will run three Phase Ib clinical trials in Australia and New Zealand testing its humanised monoclonal antibody therapies for cancer.

The three separate trials, which have begun enrollment, are targeting patients pancreatic cancer, advanced colorectal cancer, and non-squamous non-small cell lung cancer (NSCLC).

OncoMed's treatments use monoclonal antibodies to target specific biologic pathways that are critical to tumour initiating cells, or so-called 'cancer stem cells'.

The trials will be run in Australia and New Zealand through the Sydney-based contract research organisation, Novotech.

Related News

Biomaterial helps to reverse aging in the heart

The discovery could open the door to therapies that rejuvenate the heart by changing its cellular...

Anti-inflammatory agent could decrease septic shock mortality

Researchers have discovered a naturally occurring blood protein — a type of...

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd